Quince Therapeutics Presents Phase 3 ATTeST Trial Safety Data at CNS Annual Meeting
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on using patients’ own biology to treat rare diseases, presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem) clinical trial at the 53rd Child Neurology…